Pfizer reported Q1 revenues of $14.5bn, with adjusted EPS down 18% and a 6.54% dividend yield. Click here to read my most recent analysis of PFE stock.
Executive chairman Gildo Zegna said the group's 2.5 percent increase in the first quarter of 2026 was driven by strong direct-to-consumer growth and the Americas.
AstraZeneca delivered robust Q1 2026 results, with revenues up 8% year-on-year and operating profit rising 17%. Click here to read my most recent analysis.